Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib + gefitinib vs chemotherapy in MET-positive EGFR-mutant NSCLC after EGFR TKI resistance
jRCT2080223491Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck KGaA. Started Mar 2017; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223491.